Neighborhood socioeconomic deprivation, tumor subtypes, and causes of death after non-metastatic invasive breast cancer diagnosis: a multilevel competing-risk analysis

Breast Cancer Research and Treatment

Volumn 147, Issue 3, 2014, Pages 661-670

  Lian, Min ^a,b   Pérez, Maria ^a   Liu, Ying ^a   Schootman, Mario ^b,c   Frisse, Ann ^a   Foldes, Ellen ^d   Jeffe, Donna B ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MO   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

Author keywords

Breast cancer; Competing risk; Mortality; Multilevel analysis; Neighborhood socioeconomic deprivation; Subtype

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER THERAPY; CAUSE OF DEATH; COMORBIDITY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEALTH BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; NEIGHBORHOOD; POPULATION RESEARCH; PRIMARY TUMOR; RISK ASSESSMENT; SOCIAL ISOLATION; SOCIAL STATUS; SOCIOECONOMIC DEPRIVATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR CLASSIFICATION; TUMOR INVASION; AFRICAN AMERICAN; BREAST NEOPLASMS; ETHNOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; RISK FACTOR; SOCIOECONOMICS; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; BREAST NEOPLASMS; CAUSE OF DEATH; COMORBIDITY; FEMALE; HUMANS; MIDDLE AGED; MISSOURI; MULTIVARIATE ANALYSIS; RESIDENCE CHARACTERISTICS; RISK FACTORS; SOCIOECONOMIC FACTORS; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS; YOUNG ADULT;

EID: 84918815177     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3135-z     Document Type: Article

References (38)

1. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute (2004) President’s Cancer Panel. 2003–2004 Annual Report. Living beyond cancer: finding a new balance. http://deainfo.nci.nih.gov/advisory/pcp/annualReports/pcp03-04rpt/Survivorship.pdf. Accessed 30 Oct 2013
2. Bradley CJ, Given CW, Roberts C (2002) Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 94:490–496
3. Downing A, Prakash K, Gilthorpe MS, Mikeljevic JS, Forman D (2007) Socioeconomic background in relation to stage at diagnosis, treatment and survival in women with breast cancer. Br J Cancer 96:836–840
4. Bastiaannet E, de Craen AJ, Kuppen PJ, Aarts MJ, van der Geest LG et al (2011) Socioeconomic differences in survival among breast cancer patients in the Netherlands not explained by tumor size. Breast Cancer Res Treat 127:721–727
5. Akinyemiju TF, Soliman AS, Johnson NJ, Altekruse SF, Welch K et al (2013) Individual and neighborhood socioeconomic status and healthcare resources in relation to black-white breast cancer survival disparities. J Cancer Epidemiol 2013:490472
6. Tannenbaum SL, Koru-Sengul T, Miao F, Byrne MM (2013) Disparities in survival after female breast cancer diagnosis: a population-based study. Cancer Causes Control 24:1705–1715
7. Markossian TW, Hines RB, Bayakly R (2014) Geographic and racial disparities in breast cancer-related outcomes in Georgia. Health Serv Res 49:481–501
8. Thomson CS, Hole DJ, Twelves CJ, Brewster DH, Black RJ et al (2001) Prognostic factors in women with breast cancer: distribution by socioeconomic status and effect on differences in survival. J Epidemiol Community Health 55:308–315
9. Harper S, Lynch J, Meersman SC, Breen N, Davis WW et al (2009) Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987–2005). Cancer Epidemiol Biomarkers Prev 18:121–131
10. Sprague BL, Trentham-Dietz A, Gangnon RE, Ramchandani R, Hampton JM et al (2011) Socioeconomic status and survival after an invasive breast cancer diagnosis. Cancer 117:1542–1551
11. Cross SK, Harris J, Recht A (2002) Race, Socioeconomic status, and breast carcinoma in the US: what have we learned from clinical studies. Cancer 95:1988–1999
12. Rutqvist LE, Bern A, Stockholm Breast Cancer Study G (2006) Socioeconomic gradients in clinical stage at presentation and survival among breast cancer patients in the Stockholm area 1977-1997. Int J Cancer 119:1433–1439
13. Vona-Davis L, Rose DP (2009) The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt) 18:883–893
14. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728
15. Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U et al (2009) Triple-negative breast cancer–current status and future directions. Ann Oncol 20:1913–1927
16. Colzani E, Liljegren A, Johansson AL, Adolfsson J, Hellborg H et al (2011) Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol 29:4014–4021
17. Patnaik JL, Byers T, Diguiseppi C, Denberg TD, Dabelea D (2011) The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst 103:1101–1111
18. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R (2000) Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160:953–958
19. Ly BH, Nguyen NP, Vinh-Hung V, Rapiti E, Vlastos G (2010) Loco-regional treatment in metastatic breast cancer patients: is there a survival benefit? Breast Cancer Res Treat 119:537–545
20. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795
21. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145
22. Lian M, Schootman M, Doubeni CA, Park Y, Major JM et al (2011) Geographic variation in colorectal cancer survival and the role of small-area socioeconomic deprivation: a multilevel survival analysis of the NIH-AARP diet and health study cohort. Am J Epidemiol 174:828–838
23. Lian M, Struthers J, Schootman M (2012) Comparing GIS-based measures in access to mammography and their validity in predicting neighborhood risk of late-stage breast cancer. PLoS One 7:e43000
24. Kim HT (2007) Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 13:559–565
25. Allison PD (2010) Survival analysis using SAS: a practical guide, 2nd edn. SAS Press, Cary, North Carolina
26. Chaix B, Rosvall M, Lynch J, Merlo J (2006) Disentangling contextual effects on cause-specific mortality in a longitudinal 23-year follow-up study: impact of population density or socioeconomic environment? Int J Epidemiol 35:633–643
27. Piccirillo JF, Costas I, Claybour P, Borah AJ, Grove L et al (2003) The measurement of comorbidity by cancer registries. J Registry Manag 30:8–14
28. Lunn M, McNeil D (1995) Applying cox regression to competing risks. Biometrics 51:524–532
29. Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE et al (2012) Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat 131:159–167
30. Schairer C, Mink PJ, Carroll L, Devesa SS (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96:1311–1321
31. Chapman JA, Meng D, Shepherd L, Parulekar W, Ingle JN et al (2008) Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 100:252–260
32. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD (2011) Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 13:R64
33. Azim HA Jr, de Azambuja E, Colozza M, Bines J, Piccart MJ (2011) Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol 22:1939–1947
34. Telli ML, Hunt SA, Carlson RW, Guardino AE (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25:3525–3533
35. Satariano WA, Ragland DR (1994) The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104–110
36. Lonning PE (2012) Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions. Ther Adv Med Oncol 4:127–137
37. Dawood S, Broglio K, Kau SW, Green MC, Giordano SH et al (2009) Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27:220–226
38. Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX (2013) Racial differences in outcomes of triple-negative breast cancer. Breast Cancer Res Treat 138:281–289